Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
The purpose of this research is to evaluate changes in cholinergic brain activity over time
 in subjects with Parkinson disease.
The project will apply positron emission tomography (PET) of acetylcholinesterase to study
 non-dopaminergic (i.e. cholinergic) brain changes over time in subjects with Parkinson
 disease. Acetylcholinesterase PET imaging was used to assess cholinergic changes over time in
 this study. Acetylcholinesterase PET imaging is a diagnostic test as the investigator does
 not assign specific interventions to the subjects of the study based on the
 acetylcholinesterase PET. Therefore, this is an observational study as defined as following:
 studies in human beings in which biomedical and/or health outcomes are assessed in
 pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic,
 or other interventions, but the investigator does not assign specific interventions to the
 subjects of the study.
Inclusion Criteria:

 -  Patients who meet the UK Parkinson's Disease Society Brain Bank Research Center
 clinical diagnostic criteria for PD.

 -  Hoehn and Yahr stages 1-2.5 at initial recruitment in baseline study.

 -  Absence of dementia confirmed by neuropsychological testing at initial recruitment in
 baseline study.

 Exclusion Criteria:

 -  contra-indication for magnetic resonance study

 -  Pregnancy or breastfeeding